Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Melanoma Immunotherapy and Dermatological Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Tyrosinase (TYR) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human Tyrosinase (TYR) (ECD, His-Tag) HEK293 expressed for native glycosylation. High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. |
View TYR Products |
| Gene Delivery | TYR Promise-ORF / Lentivirus Full-length human TYR ORF for stable cell line generation and cell-based melanin assays. |
View TYR Products |
| Benchmark Ab | Recombinant Anti-TYR Antibody Recombinant positive control derived from high-affinity benchmark clones (e.g., T311) for IHC, Flow Cytometry, and ELISA. |
View TYR Products |
| Validator | TYR siRNA Set Target-specific siRNA pool for knockdown verification in melanocytes and melanoma cell lines. |
View TYR Products |
| Related Target A | TYRP1 (Tyrosinase-Related Protein 1) Downstream melanogenic enzyme; critical counter-screening target for selectivity assays. |
View TYRP1 Products |
| Related Target B | DCT / TYRP2 (Dopachrome Tautomerase) Key enzyme in the eumelanin synthesis pathway; co-target for comprehensive pigmentation studies. |
View TYRP2 Products |
| Related Target C | MITF (Microphthalmia-Associated Transcription Factor) Master regulator of TYR, TYRP1, and DCT expression; essential upstream pathway node. |
View MITF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mushroom vs. Human TYR Divergence | Active Human Recombinant TYR expressed in HEK293, avoiding false positives from non-human surrogates. |
| Glycosylation-Dependent Activity | HEK293 eukaryotic host expression ensures native post-translational modifications and correct folding. |
| Lack of Validated Controls | Clinical-grade benchmark antibodies and sequence-verified positive controls included. |
| Off-Target Cross-Reactivity | Homolog screening panel (TYRP1 and DCT) available for high-throughput selectivity profiling. |
Live Tyrosinase (TYR) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Tyrosinase (TYR) spans two distinct industries: oncology and dermatology. In oncology, TYR is a well-established tumor-associated antigen (TAA) highly expressed in melanoma. Clinical development is shifting from traditional peptide vaccines to advanced modalities, including mRNA-based cancer vaccines, TCR-T cell therapies targeting TYR-derived HLA-presented peptides, and bispecific T-cell engagers (BiTEs). In dermatology and cosmetics, the focus remains on identifying highly selective, non-toxic small molecule inhibitors of human TYR to treat hyperpigmentation disorders, moving away from legacy compounds with poor safety profiles like hydroquinone.
As next-generation immunotherapies and cosmetic actives enter rigorous clinical evaluation, the demand for highly purified, natively folded human TYR protein—rather than fungal surrogates—is paramount to ensuring clinical translation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T / CAR-T | Academic Medical Centers, Biotech Startups | Metastatic Melanoma | HLA-peptide complex validation (Requires high-purity TYR peptides and recombinant proteins) |
| Cancer Vaccines (mRNA/Peptide) | BioNTech, Moderna, Oncqaure | Adjuvant Melanoma Therapy | Humoral response monitoring (Requires sequence-verified TYR antigens for ELISA) |
| Small Molecule Inhibitors | Estée Lauder, L'Oréal, Shiseido, Pharma Corporates | Hyperpigmentation, Melasma, Age Spots | High-throughput enzyme inhibition assays (Requires active, HEK293-expressed Human TYR) |